Amber Salzman
Directeur Général chez Epicrispr Biotechnologies, Inc.
Profil
Dr. Amber Salzman is a President at The Stop ALD Foundation, a Chief Executive Officer at Epicrispr Biotechnologies, Inc. and a President, Chief Executive Officer & Director at Ohana Biosciences, Inc. She is on the Board of Directors at Ald Connect, Inc., Drexel University School of Public Health, AviadoBio Ltd., Ohana Biosciences, Inc. and Lankenau Institute for Medical Research.
Dr. Salzman was previously employed as a President, Chief Executive Officer & Director by Adverum Biotechnologies, Inc., a President & Chief Executive Officer by Annapurna Therapeutics SAS, a President & Chief Executive Officer by CardioKine, Inc., and a Member-Research & Development Executive Team by GSK Plc.
She also served on the board at Akcea Therapeutics, Inc. She received her undergraduate degree from Temple University (Pennsylvania) and a doctorate degree from Bryn Mawr College.
Postes actifs de Amber Salzman
| Sociétés | Poste | Début |
|---|---|---|
The Stop ALD Foundation
 The Stop ALD Foundation Miscellaneous Commercial ServicesCommercial Services The Stop ALD Foundation is a non-profit organization based in Houston that focuses on accelerating the process of developing new knowledge and new therapies for adrenoleukodystrophy (ALD). ALD is a deadly genetic disease that affects 1 in 18,000 people, most severely affecting boys and men. This brain disorder destroys myelin, the protective sheath that surrounds the brain's neurons, and it knows no racial, ethnic, or geographic barriers. The foundation's mission is to develop therapies for ALD and raise awareness about the disease. | President | 01/03/2001 |
| Drexel University School of Public Health | Directeur/Membre du Conseil | - |
Ald Connect, Inc.
 Ald Connect, Inc. Services to the Health IndustryHealth Services Ald Connect, Inc. is a non-profit organization that aims to improve health outcomes for patients with adrenoleukodystrophy (ALD) by empowering patients, raising awareness, and accelerating the translation of scientific advances into better clinical care. The non-profit company is based in Middleton, MA, USA. ALD is a rare genetic disease that affects the adrenal glands, the spinal cord, and the white matter of the nervous system. Ald Connect offers various opportunities to get involved with their community, including advocacy, fundraising, volunteering, and participating in their programs or events. | Directeur/Membre du Conseil | - |
Ohana Biosciences, Inc.
 Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | Directeur Général | 01/07/2018 |
Lankenau Institute for Medical Research
 Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | Directeur/Membre du Conseil | - |
AviadoBio Ltd.
 AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Directeur/Membre du Conseil | - |
Epicrispr Biotechnologies, Inc.
 Epicrispr Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman. | Directeur Général | - |
Anciens postes connus de Amber Salzman
| Sociétés | Poste | Fin |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 12/10/2020 |
| ADVERUM BIOTECHNOLOGIES, INC. | Directeur Général | 03/05/2018 |
| ░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Amber Salzman
| Temple University (Pennsylvania) | Undergraduate Degree |
| Bryn Mawr College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 9 |
|---|---|
CardioKine, Inc.
 CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Annapurna Therapeutics SAS
 Annapurna Therapeutics SAS BiotechnologyHealth Technology Annapurna Therapeutics SAS operates as a gene therapy company. Its therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. The company was founded by Pierre Bougneres, Hélène Puccio, Amber Salzman, Patrick Aubourg and Ronald G. Crystal and is headquartered in Paris, France. | Health Technology |
The Stop ALD Foundation
The Stop ALD Foundation Miscellaneous Commercial ServicesCommercial Services The Stop ALD Foundation is a non-profit organization based in Houston that focuses on accelerating the process of developing new knowledge and new therapies for adrenoleukodystrophy (ALD). ALD is a deadly genetic disease that affects 1 in 18,000 people, most severely affecting boys and men. This brain disorder destroys myelin, the protective sheath that surrounds the brain's neurons, and it knows no racial, ethnic, or geographic barriers. The foundation's mission is to develop therapies for ALD and raise awareness about the disease. | Commercial Services |
Ald Connect, Inc.
Ald Connect, Inc. Services to the Health IndustryHealth Services Ald Connect, Inc. is a non-profit organization that aims to improve health outcomes for patients with adrenoleukodystrophy (ALD) by empowering patients, raising awareness, and accelerating the translation of scientific advances into better clinical care. The non-profit company is based in Middleton, MA, USA. ALD is a rare genetic disease that affects the adrenal glands, the spinal cord, and the white matter of the nervous system. Ald Connect offers various opportunities to get involved with their community, including advocacy, fundraising, volunteering, and participating in their programs or events. | Health Services |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | Commercial Services |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Health Technology |
Epicrispr Biotechnologies, Inc.
Epicrispr Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman. | Commercial Services |
